{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:30:35Z","timestamp":1778859035667,"version":"3.51.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":212,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.lpm.2023.104178","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T16:36:08Z","timestamp":1696091768000},"page":"104178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years"],"prefix":"10.1016","volume":"52","author":[{"given":"Tomasz J.","family":"Block","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-2488","authenticated-orcid":false,"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lpm.2023.104178_bib0001","first-page":"97","article-title":"Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (author's transl)","volume":"3","author":"Pirart","year":"1977","journal-title":"Diabete Metab"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0002","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2337\/diacare.1.3.168","article-title":"Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973","volume":"1","author":"Pirart","year":"1978","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.lpm.2023.104178_bib0003","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/diacare.1.4.252","article-title":"Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973","volume":"1","author":"Pirart","year":"1978","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1016\/j.lpm.2023.104178_bib0004","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.lpm.2023.104178_bib0005","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1001\/jama.290.16.2159","article-title":"Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study","volume":"290","year":"2003","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.lpm.2023.104178_bib0006","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"Ian H de Boer","year":"2011","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104178_bib0007","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"issue":"23","key":"10.1016\/j.lpm.2023.104178_bib0008","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1806802","article-title":"Intensive glucose control in patients with type 2 diabetes \u2014 15-year follow-up","volume":"380","author":"Reaven","year":"2019","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104178_bib0009","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.lpm.2023.104178_bib0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"New Engl J Med"},{"issue":"24","key":"10.1016\/j.lpm.2023.104178_bib0011","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0012","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.lpm.2023.104178_bib0013","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2337\/diacare.4.4.459","article-title":"Reduced albuminuria during early and aggressive antihypertensive treatment of insulin-dependent diabetic patients with diabetic nephropathy","volume":"4","author":"Parving","year":"1981","journal-title":"Diabetes Care"},{"issue":"6343","key":"10.1016\/j.lpm.2023.104178_bib0014","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/bmj.285.6343.685","article-title":"Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy","volume":"285","author":"Mogensen","year":"1982","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.lpm.2023.104178_bib0015","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.lpm.2023.104178_bib0016","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF00265552","article-title":"Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat","volume":"32","author":"Cooper","year":"1989","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.lpm.2023.104178_bib0017","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2337\/diacare.46.10.1612","article-title":"Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies","volume":"46","author":"Allen","year":"1997","journal-title":"Diabetes"},{"issue":"6656","key":"10.1016\/j.lpm.2023.104178_bib0018","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.297.6656.1092","article-title":"Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria","volume":"297","author":"Marre","year":"1988","journal-title":"Bmj"},{"issue":"20","key":"10.1016\/j.lpm.2023.104178_bib0019","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104178_bib0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","year":"2001","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.lpm.2023.104178_bib0021","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lpm.2023.104178_bib0022","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lpm.2023.104178_bib0023","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104178_bib0024","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.lpm.2023.104178_bib0025","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0026","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2337\/diabetes.47.3.414","article-title":"Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition","volume":"47","author":"Gilbert","year":"1998","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.lpm.2023.104178_bib0027","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s001250100546","article-title":"Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension","volume":"44","author":"Bonnet","year":"2001","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.lpm.2023.104178_bib0028","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s001250100561","article-title":"Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade","volume":"44","author":"Mifsud","year":"2001","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.lpm.2023.104178_bib0029","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ncpneph0192","article-title":"Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy","volume":"2","author":"Epstein","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"issue":"5","key":"10.1016\/j.lpm.2023.104178_bib0030","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.lpm.2023.104178_bib0031","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.lpm.2023.104178_bib0032","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","author":"Pitt","year":"2021","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104178_bib0033","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.lpm.2023.104178_bib0034","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1517\/13543776.15.11.1531","article-title":"Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents","volume":"15","author":"Handlon","year":"2005","journal-title":"Expert Opin Ther Pat"},{"issue":"18","key":"10.1016\/j.lpm.2023.104178_bib0035","first-page":"1801","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2023.104178_bib0036","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2013a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0037","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"10.1016\/j.lpm.2023.104178_bib0038","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2023.104178_bib0039","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lpm.2023.104178_bib0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1016\/j.lpm.2023.104178_bib0041","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.lpm.2023.104178_bib0042","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2023.104178_bib0043","first-page":"117","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2022","journal-title":"New Engl J Med"},{"issue":"15","key":"10.1016\/j.lpm.2023.104178_bib0044","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"New Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2023.104178_bib0045","first-page":"S151","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"issue":"4s","key":"10.1016\/j.lpm.2023.104178_bib0046","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"issue":"Supplement_1","key":"10.1016\/j.lpm.2023.104178_bib0047","first-page":"S125","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022","volume":"45","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.lpm.2023.104178_bib0048","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41581-021-00475-7","article-title":"Potential cardiorenal benefits of efpeglenatide in diabetes","volume":"17","author":"Ma","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"23","key":"10.1016\/j.lpm.2023.104178_bib0049","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2023.104178_bib0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med"},{"issue":"13","key":"10.1016\/j.lpm.2023.104178_bib0051","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"New Engl J Med"},{"issue":"10193","key":"10.1016\/j.lpm.2023.104178_bib0052","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10157","key":"10.1016\/j.lpm.2023.104178_bib0053","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lpm.2023.104178_bib0054","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1016\/j.lpm.2023.104178_bib0055","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2023.104178_bib0056","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.lpm.2023.104178_bib0057","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","article-title":"GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases","volume":"61","author":"Hendarto","year":"2012","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0058","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.lpm.2023.104178_bib0059","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.lpm.2023.104178_bib0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.lpm.2023.104178_bib0061","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2023.104178_bib0062","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.lpm.2023.104178_bib0063","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.lpm.2023.104178_bib0064","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10193","key":"10.1016\/j.lpm.2023.104178_bib0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lpm.2023.104178_bib0066","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/dom.13847","article-title":"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diab Obes Metabol"},{"key":"10.1016\/j.lpm.2023.104178_bib0067","unstructured":"ClinicalTrials.gov. A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW) 2020 [cited 2022 20\/09\/2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819153."},{"issue":"10295","key":"10.1016\/j.lpm.2023.104178_bib0068","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0069","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New Engl J Med"},{"issue":"10313","key":"10.1016\/j.lpm.2023.104178_bib0070","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2023.104178_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","author":"Heerspink","year":"2022","journal-title":"Lancet Diab Endocrinol"},{"issue":"11","key":"10.1016\/j.lpm.2023.104178_bib0072","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.lpm.2023.104178_bib0073","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen","volume":"63","author":"Kanasaki","year":"2014","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0074","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bbrc.2013.12.049","article-title":"Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes","volume":"443","author":"Kodera","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.ajkd.2015.03.024","article-title":"Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes","volume":"66","author":"Cooper","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"14","key":"10.1016\/j.lpm.2023.104178_bib0076","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.lpm.2023.104178_bib0077","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lpm.2023.104178_bib0078","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS","volume":"39","author":"Cornel","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.lpm.2023.104178_bib0079","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.lpm.2023.104178_bib0080","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2337\/dc20-0279","article-title":"Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial","volume":"43","author":"Perkovic","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.lpm.2023.104178_bib0081","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.lpm.2023.104178_bib0082","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.lpm.2023.104178_bib0083","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.lpm.2023.104178_bib0084","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"10184","key":"10.1016\/j.lpm.2023.104178_bib0085","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lpm.2023.104178_bib0086","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1172\/JCI99768","article-title":"ASK1 contributes to fibrosis and dysfunction in models of kidney disease","volume":"128","author":"Liles","year":"2018","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.lpm.2023.104178_bib0087","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of selonsertib in patients with diabetic kidney disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J Am Soc Nephrol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498223000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498223000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:37Z","timestamp":1760105437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498223000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0755498223000155"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2023.104178","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2023.104178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104178"}}